Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial
- Submitting institution
-
The University of Manchester
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 85032408
- Type
- D - Journal article
- DOI
-
10.1016/S0140-6736(18)32984-2
- Title of journal
- Lancet (London, England)
- Article number
- -
- First page
- 229
- Volume
- 393
- Issue
- 10168
- ISSN
- 0140-6736
- Open access status
- Other exception
- Month of publication
- December
- Year of publication
- 2018
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
31
- Research group(s)
-
A - Cancer Sciences
- Citation count
- 144
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- I was involved in study conception, design, and organisation and conduct, data interpretation, and writing and critiquing the intellectual content of the paper.
- Non-English
- No
- English abstract
- -
